

LAUSANNE, APRIL 26, 2022

PERFECT HOLDING SA PUBLISHES THE FOLLOWING AD HOC ANNOUNCEMENT  
PURSUANT TO ART. 53 LR:

# PERFECT HOLDING REPORTS A PRESS RELEASE OF KINARUS

As announced on March 30, 2022, Perfect Holding has signed a transaction agreement with the clinical-stage biopharmaceutical company Kinarus AG ("Kinarus") regarding Perfect Holding's planned acquisition of Kinarus by way of a share exchange.

The transaction is still subject to the approval of Perfect Holding's shareholders (at the shareholders' meeting of May 2, 2022) and the approval by SIX Swiss Exchange of the listing of the new shares of Perfect Holding to be issued to the shareholders of Kinarus, following the recent approval of the transaction by the shareholders of Kinarus with the required qualified majority of 66%.

In this context, Perfect Holding announces that Kinarus ([www.kinarus.com](http://www.kinarus.com)) has published the following press release on April 26, 2022:

## **KINARUS RECEIVES GRANT OF KEY U.S. PATENT FOR ITS LEAD THERAPEUTIC CANDIDATE**

■ **Grant of KIN001 composition of matter patent strengthens proprietary position in U.S. until at least 2037.**

Basel, Switzerland, April 26, 2022. Kinarus AG ("Kinarus") announced today that the United States Patent and Trademark Office (USPTO) has issued US Patent No. 11285155 entitled "Pharmaceutical Combinations for Treating Cancer" that covers the Kinarus lead therapeutic candidate KIN001.

The composition of matter claim of the granted U.S. Patent protects the KIN001 pharmaceutical combination of pamapimod and pioglitazone until at least 2037. This allowance adds to the prior granted European patent, EP3468604 B1, which has been validated in the majority of European countries. The composition of matter claim of the granted U.S. and European patents provide protection of the KIN001 pharmaceutical combination, irrespective of therapeutic indication. Kinarus is currently developing KIN001 as an oral treatment for COVID-19 and has plans to develop KIN001 in wet-age-related macular degeneration and idiopathic pulmonary fibrosis. The granted U.S and European patents also provide Method of Use Claims for the combination of pamapimod and pioglitazone for the treatment of cancer such as lung cancer, ovarian cancer, and cancer of the GI tract. Patents have also been allowed or granted in ARIPO (African Regional IP Organization), Columbia, Hong Kong, Israel, Mexico, Ukraine, South Africa, and are pending in other jurisdictions.

Dr. Alexander Bausch, Kinarus CEO, commented: "We are delighted with the decision of the United States Patent and Trademark Office to grant this important patent for KIN001. This grant, together with the European patent granted in 2021, protects the pharmaceutical composition of KIN001, and provides a secure IP foundation for exploration of its potential across multiple indications."